Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP9 | Q86TI2 | 8/20 | 0.58 |
| ▸ | PREP | P48147 | 6/20 | 0.58 |
| ▸ | DPP4 | P27487 | 5/20 | 0.58 |
| ▸ | FAP | Q12884 | 7/20 | 0.52 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.52 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27347253 | 0.90 | DPP9 (0.59) | DPP9PREPDPP4FAPDPP8 | |
| SCHEMBL25499546 | 0.89 | DPP9 (0.61) | DPP9PREPDPP4FAPDPP8 | |
| SCHEMBL27347157 | 0.85 | DPP9 (0.55) | DPP9PREPDPP4FAPDPP8 | |
| SCHEMBL26764256 | 0.77 | DPP9 (0.60) | DPP9PREPDPP4FAPDPP8 | |
| SCHEMBL15130011 | 0.73 | DPP9 (1.00) | DPP9PREPDPP4FAPDPP8 | |
| SCHEMBL15130010 | 0.73 | DPP9 (1.00) | DPP9PREPDPP4FAPDPP8 | |
| SCHEMBL23567893 | 0.73 | DPP9 (0.86) | DPP9PREPDPP4FAPDPP8 | |
| SCHEMBL26231103 | 0.73 | PREP (0.77) | DPP9PREPDPP4FAP | |
| SCHEMBL26839934 | 0.72 | DPP9 (0.72) | DPP9PREPDPP4FAPDPP8 | |
| SCHEMBL31505495 | 0.72 | DPP9 (0.75) | DPP9PREPDPP4FAPDPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159495-A1 | COMPOUND OR ITS SALT THEREOF TARGETING FIBROBLAST ACTIVATION PROTEIN, ITS PREPARATION METHODS AND ITS USES THEREOF | INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, R.O.C. (TW) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159495-A1 | COMPOUND OR ITS SALT THEREOF TARGETING FIBROBLAST ACTIVATION PROTEIN, ITS PREPARATION METHODS AND ITS USES THEREOF | FIBP, FGFR2, FGFR1 | DPP9 1271/4885PREP 2530/4885DPP4 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.